Passage Bio, Inc. (PASG) Stock Forecast
PASG analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 3.67 / 5 from 3 analysts
- Price target
- $15.50 average of analyst targets
- Upside to target
- +342.9% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-2.16
- 52-week range
- $3.50 – $19.85
PASG analyst ratings
3 analystsNumber of analysts at each rating.
PASG price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PASG earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$2.82 | −$3.75 | −$1.89 | −$2.44 | −15.6% | 2 |
| Current fiscal year (2026) | −$11.34 | −$14.08 | −$8.60 | −$14.35 | +21.0% | 2 |
| Next fiscal year (2027) | −$10.39 | −$11.55 | −$9.23 | −$11.34 | +8.4% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PASG revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 2 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 3 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 3 |
PASG EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PASG EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$2.53 | −$3.01 | −$2.82 | −$2.82 | −$2.82 | +11.6% | 0 up · 0 down |
| Current fiscal year (2026) | −$9.36 | −$10.85 | −$11.34 | −$11.34 | −$11.34 | +21.2% | 0 up · 0 down |
| Next fiscal year (2027) | −$7.68 | −$10.39 | −$10.39 | −$10.39 | −$10.39 | +35.3% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PASG earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PASG beat in 8 of 12.
What analysts expect from PASG
3 analysts cover Passage Bio; their consensus rating is buy (3.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $15.50, 342.9% above the latest close of $3.50. Analysts expect earnings of −$11.34 per share for 2026, +21.0% from a year earlier. For 2027 the average estimate is −$10.39 per share. Passage Bio beat the EPS estimate in 8 of the last 12 quarters.
Related: PASG income statement, PASG key metrics, PASG chart. See the PASG stock overview for the latest quote and news.
PASG forecast FAQ
What is Passage Bio's price target?
The average analyst price target for Passage Bio is $15.50, 342.9% above the latest close of $3.50.
Is Passage Bio a buy, hold or sell?
Of 3 analysts covering Passage Bio, 1 rate it a strong buy, 0 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Passage Bio's EPS forecast?
Analysts forecast −$11.34 per share for 2026 (range −$14.08 to −$8.60); for 2027 the estimate is −$10.39.
When does Passage Bio report earnings?
Passage Bio is expected to report results for the quarter ending September 30, 2026 on November 9, 2026; the EPS estimate is $-2.16.
Does Passage Bio usually beat earnings estimates?
Passage Bio reported EPS at or above the analyst estimate in 8 of the last 12 quarters.